Anika Therapeutics, Inc. is a joint preservation company that develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology. Co.'s OA Pain Management products, Monovisc and Orthovisc, provide pain relief for osteoarthritis, while Cingal combines cross-linked HA with a fast-acting steroid. The Joint Preservation and Restoration segment includes orthopedic regenerative solutions like Integrity, Tactoset, and Hyalofast, sports medicine solutions for ligament and tendon repair, and Arthrosurface technologies for joint preservation. The Non-Orthopedic segment offers products for adhesion barriers, advanced wound care, and ENT applications. We show 63 historical shares outstanding datapoints in our coverage of ANIK's shares outstanding history.
Understanding the changing numbers of ANIK shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ANIK versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ANIK by allowing them to research ANIK shares outstanding history
as well as any other stock in our coverage universe. |
Free ANIK Email Alerts:
Video: Shares Outstanding Importance
